Dolan Matthew Vincent
SEC CIK 1914994 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| DXCM | Dexcom | SVP Corp. Strategy-Develop | 42.0K | — | $4.02M | 17 | 2022-03-08 | 2025-01-29 |
Most active insiders at DXCM, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | SAYER KEVIN R | Executive COB, Dir | — | $8.30M |
| 2 | Leach Jacob Steven | Pres, COO | $1.00M | — |
| 3 | Brown Michael Jon | EVP, CLO | — | $873.4K |
| 4 | Coleman Jon | EVP, Chief Commercial Off | — | $722.6K |
| 5 | AUGUSTINOS NICHOLAS | Dir | — | $679.8K |
| 6 | FOLETTA MARK G | Dir | — | $627.2K |
| 7 | Collins Richard Alexander | Dir | — | $389.4K |
| 8 | Sylvain Jereme M | EVP, Chief Financal Off | — | $302.9K |
| 9 | Heller Bridgette P | Dir | — | $277.7K |
| 10 | Stern Sadie | EVP, Chief HR Off | — | $226.7K |
Dolan Matthew Vincent made no open-market trades at DXCM in the last 12 months.
Transactions 17
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-30 | 2025-01-28 | DXCM | Dexcom | Dolan Matthew Vincent | EVP, Strategy, Corp. Dev | A - Grant | $0.00 | +3,048 | 43.2K | +8% | $0 | |
| 2025-01-30 | 2025-01-29 | DXCM | Dexcom | Dolan Matthew Vincent | EVP, Strategy, Corp. Dev | S - Sale | $86.91 | -1,183 | 42.0K | -3% | -$102.8K | |
| 2024-05-16 | 2024-05-15 | DXCM | Dexcom | Dolan Matthew Vincent | EVP Strategy, Corp. Dev | S - Sale | $126.58 | -2,423 | 40.1K | -6% | -$306.7K | |
| 2024-04-16 | 2024-04-15 | DXCM | Dexcom | Dolan Matthew Vincent | EVP Strategy, Corp. Dev | S - Sale | $137.81 | -1,990 | 42.4K | -4% | -$274.2K | |
| M | 2024-03-19 | 2024-03-15 | DXCM | Dexcom | Dolan Matthew Vincent | EVP Strategy, Corp Dev | S - Sale | $130.20 | -4,203 | 44.4K | -9% | -$547.2K |
| 2024-03-14 | 2024-03-12 | DXCM | Dexcom | Dolan Matthew Vincent | EVP Strategy, Corp | S - Sale | $134.41 | -6,710 | 48.6K | -12% | -$901.9K | |
| 2024-03-11 | 2024-03-08 | DXCM | Dexcom | Dolan Matthew Vincent | EVP Strategy, Corp | A - Grant | $0.00 | +21.7K | 55.3K | +65% | $0 | |
| 2023-09-01 | 2023-09-01 | DXCM | Dexcom | Dolan Matthew Vincent | SVP Corp. Strategy-Develop | S - Sale | $102.32 | -56 | 33.6K | -0.2% | -$5,730 | |
| 2023-03-17 | 2023-03-16 | DXCM | Dexcom | Dolan Matthew Vincent | SVP Corp. Strategy-Develop | S - Sale | $115.00 | -2,303 | 33.6K | -6% | -$264.8K | |
| 2023-03-14 | 2023-03-13 | DXCM | Dexcom | Dolan Matthew Vincent | SVP Corp. Strategy-Develop | S - Sale | $106.27 | -6,229 | 35.9K | -15% | -$662.0K | |
| M | 2023-03-14 | 2023-03-10 | DXCM | Dexcom | Dolan Matthew Vincent | SVP Corp. Strategy-Develop | D - Sale to Iss | $111.40 | -6,204 | 46.9K | -12% | -$691.1K |
| 2023-03-10 | 2023-03-08 | DXCM | Dexcom | Dolan Matthew Vincent | SVP Corp. Strategy-Develop | A - Grant | $0.00 | +21.8K | 48.3K | +82% | $0 | |
| 2023-03-06 | 2023-03-06 | DXCM | Dexcom | Dolan Matthew Vincent | SVP Corp. Strategy-Develop | S - Sale | $114.40 | -226 | 26.5K | -0.8% | -$25.9K | |
| 2022-09-06 | 2022-09-01 | DXCM | Dexcom | Dolan Matthew Vincent | SVP Corp. Strategy-Develop | S - Sale | $81.63 | -5 | 26.5K | -0.0% | -$408.15 | |
| M | 2022-03-17 | 2022-03-15+ | DXCM | Dexcom | Dolan Matthew Vincent | SVP Corp. Development | S - Sale | $424.68 | -2,186 | 7,804 | -22% | -$928.4K |
| M | 2022-03-10 | 2022-03-09 | DXCM | Dexcom | Dolan Matthew Vincent | SVP Corp. Development | D - Sale to Iss | $406.06 | -1,615 | 8,820 | -15% | -$655.8K |
| 2022-03-10 | 2022-03-08 | DXCM | Dexcom | Dolan Matthew Vincent | SVP Corp. Development | A - Grant | $0.00 | +2,889 | 10.4K | +38% | $0 |
Purchase Sale Sale after option exercise All abbreviations